EIKN (NASDAQ:EIKN) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of EIKN (NASDAQ:EIKN) from a sell rating to a hold rating in a report issued on Saturday.

Other equities research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. assumed coverage on shares of EIKN in a research note on Monday, March 2nd. They issued an “overweight” rating and a $29.00 price target on the stock. Bank of America assumed coverage on shares of EIKN in a research report on Monday, March 2nd. They set a “buy” rating and a $34.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of EIKN in a report on Monday, March 2nd. They set an “overweight” rating on the stock. Wedbush assumed coverage on shares of EIKN in a research report on Thursday, February 26th. They issued an “underperform” rating and a $7.00 target price on the stock. Finally, Zacks Research raised shares of EIKN to a “hold” rating in a research note on Friday, February 27th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $25.60.

EIKN Stock Down 6.8%

EIKN stock opened at $9.81 on Friday. EIKN has a 12 month low of $9.81 and a 12 month high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.